PensionDanmark Pensionsforsikringsaktieselskab Purchases 21,236 Shares of AbbVie Inc. $ABBV

PensionDanmark Pensionsforsikringsaktieselskab lifted its holdings in AbbVie Inc. (NYSE:ABBV) by 6.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 339,179 shares of the company’s stock after acquiring an additional 21,236 shares during the period. AbbVie makes up approximately 0.7% of PensionDanmark Pensionsforsikringsaktieselskab’s portfolio, making the stock its 22nd biggest position. PensionDanmark Pensionsforsikringsaktieselskab’s holdings in AbbVie were worth $85,351,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of ABBV. Litman Gregory Wealth Management LLC bought a new stake in AbbVie in the fourth quarter valued at $28,000. Imprint Wealth LLC raised its holdings in shares of AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after acquiring an additional 45 shares during the last quarter. IFC & Insurance Marketing Inc. bought a new position in AbbVie in the 4th quarter valued at about $31,000. Legacy Wealth Managment LLC ID lifted its position in AbbVie by 115.9% in the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after acquiring an additional 73 shares in the last quarter. Finally, WestEnd Advisors LLC boosted its stake in AbbVie by 160.4% during the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock valued at $32,000 after purchasing an additional 85 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Trading Down 1.0%

AbbVie stock opened at $243.64 on Friday. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $267.47. The business’s 50 day simple moving average is $241.40 and its 200 day simple moving average is $224.82. The company has a market cap of $430.46 billion, a price-to-earnings ratio of 68.82, a PEG ratio of 0.82 and a beta of 0.30.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The business had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The business’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period last year, the business posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities research analysts forecast that AbbVie Inc. will post 14.06 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.8%. AbbVie’s dividend payout ratio (DPR) is 195.48%.

Analysts Set New Price Targets

ABBV has been the subject of several analyst reports. Evercore set a $235.00 price objective on AbbVie in a research note on Friday, May 15th. Canaccord Genuity Group upped their price target on AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a report on Monday. Royal Bank Of Canada increased their price target on AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a research report on Friday, July 10th. Wells Fargo & Company raised their price objective on AbbVie from $260.00 to $295.00 and gave the company an “overweight” rating in a research note on Friday, July 10th. Finally, Guggenheim lifted their price objective on shares of AbbVie from $261.00 to $288.00 and gave the stock a “buy” rating in a report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and an average target price of $275.70.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie delivered a robust second quarter, with earnings and revenue exceeding analyst expectations. Revenue increased approximately 10% year over year, while management raised its revenue outlook and cited continued momentum from key products. ABBV Stock Dips 4% Despite Robust Q2
• Positive Sentiment: Analyst sentiment remains favorable. Erste Group Bank upgraded AbbVie from “hold” to “buy,” and Cantor Fitzgerald raised its price target to $285, suggesting potential upside from current levels. Cantor Fitzgerald Boosts AbbVie Price Target
• Positive Sentiment: AbbVie’s long-running dividend-growth record continues to support its appeal to income-focused investors, providing a potential floor for the stock despite valuation and acquisition concerns. This Stock Keeps Raising Its Dividend
• Neutral Sentiment: The Apogee acquisition is intended to expand AbbVie’s growth pipeline, but investors are assessing whether the strategic benefits will justify the transaction’s cost and integration risks. Baron Capital Exits Apogee Therapeutics
• Negative Sentiment: AbbVie reduced its 2026 adjusted EPS outlook to reflect the Apogee deal, offsetting the positive quarterly results and higher revenue guidance. The lower earnings forecast appears to be the main catalyst behind the stock’s decline. ABBV Stock Dips 4% Despite Robust Q2
• Negative Sentiment: AbbVie priced approximately $9.9 billion of senior notes to help fund the acquisition. The financing increases debt obligations and may intensify concerns about leverage, interest expense, and near-term shareholder returns. AbbVie Prices Senior Notes to Fund Acquisition

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.